Analysts’ Recent Ratings Changes for Rhythm Pharmaceuticals (RYTM)

Several analysts have recently updated their ratings and price targets for Rhythm Pharmaceuticals (NASDAQ: RYTM):

• 3/18/2026 – Rhythm Pharmaceuticals had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an “outperform” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Citizens Jmp from $176.00 to $152.00. They now have a “market outperform” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Bank of America Corporation from $145.00 to $139.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Needham & Company LLC from $139.00 to $130.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Rhythm Pharmaceuticals had its price target lowered by Morgan Stanley from $150.00 to $136.00. They now have an “overweight” rating on the stock.
• 3/12/2026 – Rhythm Pharmaceuticals was given a new $143.00 price target by Telsey Advisory Group.
• 3/12/2026 – Rhythm Pharmaceuticals had its price target raised by Wells Fargo & Company from $136.00 to $143.00. They now have an “overweight” rating on the stock.
• 3/3/2026 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $125.00 price target on the stock.
• 3/2/2026 – Rhythm Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $141.00 to $140.00. They now have a “buy” rating on the stock.
• 3/2/2026 – Rhythm Pharmaceuticals had its price target lowered by HC Wainwright from $125.00 to $110.00. They now have a “buy” rating on the stock.
• 2/27/2026 – Rhythm Pharmaceuticals had its price target lowered by Wells Fargo & Company from $145.00 to $136.00. They now have an “overweight” rating on the stock.
• 2/27/2026 – Rhythm Pharmaceuticals had its price target raised by Citizens Jmp from $167.00 to $176.00. They now have a “market outperform” rating on the stock.
• 2/27/2026 – Rhythm Pharmaceuticals had its price target raised by Guggenheim from $140.00 to $143.00. They now have a “buy” rating on the stock.
• 2/26/2026 – Rhythm Pharmaceuticals was given a new $131.00 price target by Stifel Nicolaus.
• 2/26/2026 – Rhythm Pharmaceuticals had its price target lowered by Needham & Company LLC from $148.00 to $139.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Rhythm Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $145.00 price target on the stock.
• 2/18/2026 – Rhythm Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $145.00 price target on the stock.
• 2/18/2026 – Rhythm Pharmaceuticals was upgraded by Royal Bank Of Canada to “moderate buy”.
• 2/17/2026 – Rhythm Pharmaceuticals was upgraded by Zacks Research from “strong sell” to “hold”.

Insider Activity

In related news, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares in the company, valued at $11,190,445.12. The trade was a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the transaction, the chief accounting officer owned 160 shares in the company, valued at $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 27,267 shares of company stock worth $2,719,955 in the last three months. Corporate insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.